Revolution Medicines, Inc. (RVMD) experienced a significant surge of 17.76% during the night session trading, driven by positive developments related to its lead drug candidate.

The sharp increase follows the company's announcement of detailed results from its global Phase 3 RASolute 302 clinical trial evaluating daraxonrasib for the treatment of metastatic pancreatic ductal adenocarcinoma. Topline data from the study showed that daraxonrasib nearly doubled median overall survival compared to standard chemotherapy, extending it to 13.2 months versus 6.7 months for chemotherapy.

This breakthrough represents a significant advancement in pancreatic cancer treatment, where RAS mutations are highly prevalent but clinically validated targeted therapies have been scarce. The positive clinical data has generated substantial market optimism, with analysts responding by reiterating Buy ratings and raising price targets based on the strong pivotal data and launch prospects for daraxonrasib.